Company intelligence / Profile preview
V2ACT Therapeutics
San Diego, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has FDA clearance for a Phase 1/2a trial of its V2ACT combination immunotherapy for newly diagnosed, surgically resectable pancreatic cancer. Early clinical and preclinical data suggest strong immune activation, a favorable safety profile, and anti-cancer efficacy for both Olvi-Vec and V-ACT; human efficacy in pancreatic cancer remains to be established in ongoing trials[1][2][3].
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic virus therapyVaccineAdoptive cell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
GeneluxTVAX Biomedical
Beyond the preview
Go deeper on V2ACT Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V2ACT Therapeutics.